Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
R&D channel feed
AstraZeneca's blockbuster Farxiga secures landmark approval in heart failure patients, regardless of whether they have diabetes
6 years ago
FDA+
J&J R&D exec Najat Khan — and data science — are getting an elevated role at the pharma giant
6 years ago
People
AI
A risky bet on a long-delayed CAR-T drug now faces a do-or-die deadline — where any slip can kill a $9 CVR
6 years ago
FDA+
Roche flashes new 16-week bispecific AMD data, setting eyes on pair of PhIII trials
6 years ago
After big 2016 setback, field of microbiome-based drugs gets injection of promise with positive signal from Rebiotix pivotal study
6 years ago
Ousted BARDA chief Rick Bright blasts HHS official for a long record of improper interference that preceded the pandemic
6 years ago
People
Akebia touts data for two PhIII studies, setting up showdown with AstraZeneca, FibroGen
6 years ago
Two years after U2 disappointment, TG Therapeutics wins back investors with PFS win — setting the stage for NDA
6 years ago
A UCSD center that's been facilitating Covid-19 clinical research gets $55M from NIH to boost translational work
6 years ago
Discovery
Praxis Precision Medicines launches with $100M and bold sights on long-evasive neurological disorders
6 years ago
Financing
Startups
Battling low expectations and goliath rivals, Regeneron/Sanofi add positive Libtayo data in pursuit of blockbuster status
6 years ago
FDA+
Alnylam, Sarepta jump into Covid-19 game, as pandemic rekindles antiviral hopes of RNA-targeting technology
6 years ago
Coronavirus
In Focus
BioMarin broadens its gene therapy horizons with a new R&D alliance in rare cardio cases
6 years ago
Deals
Cell/Gene Tx
Newron's Merck KGaA-in licensed compound fails Rett Syndrome study, shares wilt
6 years ago
FDA cheers on Gilead's remdesivir with a snap emergency OK, giving biopharma a shot at redemption
6 years ago
FDA+
Coronavirus
Tick saliva-derived drug shows promise in mid-stage rare skin disease study
6 years ago
Bristol Myers Squibb gets priority review for AML drug as list of potential Celgene hits lengthens
6 years ago
FDA+
Commercial strategy for Gilead's Covid-19 drug-to-be remdesivir remains opaque, as chief O'Day emphasizes responsibility
6 years ago
Pharma
FDA+
10X: Moderna creates a billion-dose vaccine pact in a frenzied race to beat Covid-19 — globally
6 years ago
Coronavirus
After NIH trial, EMA begins rolling review for remdesivir, setting up potential authorizations in US and Europe
6 years ago
FDA+
Coronavirus
Congressional watchdog advises HHS to implement 'post-marketing' incentives to address dwindling antibiotic development efforts
6 years ago
Data on Gilead's antiviral bring hope for first Covid-19 drug approval
6 years ago
Coronavirus
Novartis spinout resTORbio reverse merges with T cell biotech after big PhIII failure
6 years ago
Cell/Gene Tx
Gilead — Pivotal Covid-19 study of remdesivir ‘met its primary endpoint,' is emergency authorization next?
6 years ago
Coronavirus
First page
Previous page
203
204
205
206
207
208
209
Next page
Last page